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Background:	 Whilst	 robust	 preclinical	 and	 postmortem	 evidence	 suggests	 that	 altered	
GABAergic	function	is	central	to	the	development	of	psychosis,	little	is	known	about	whether	
it	 is	 altered	 in	 subjects	 at	 ultra-high	 risk	 of	 psychosis,	 or	 its	 relationship	 to	 prodromal	
symptoms.	
Methods:	 Twenty-one	 anti-psychotic	 naïve	 UHR	 individuals	 and	 20	 healthy	 volunteers	
underwent	proton	magnetic	resonance	imaging	at	3T.	GABA	levels	were	obtained	from	the	
medial	 prefrontal	 cortex	 (MPFC)	 using	 MEGA-PRESS,	 and	 expressed	 as	 peak-area	 ratios	
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	 HC	(n	=	20)	 UHR	(n	=	21)	 HC	vs.	UHR	 	
	 Mean	(SD,	range)	 Mean	(SD,	range)	 Statistic	 p	 	
Age	(years)	 23.7	(2.7,	20-28)	 22.2	(3.0,	18-29)	 t	=	1.613	 .111	 	
Estimated	IQ	 117.1	(10.4,	95-132)	 110.0	(12.5,	75-128)	 t	=	1.736	 .092	 	
CAARMS	Positive	 -	 11.9	(6.7,	1-34)	 -	 -	 	
CAARMS	Negative	 -	 8.4	(6.4,	0-29)	 -	 -	 	
Tobacco	(cigarettes/day)	 -	 4.75	(6.7)	 -	 -	
Cannabis	now	(yes/no)	 -	 11/12	 -	 -	
Cannabis	ever	(yes/no)	 -	 16/4	 -	 -	
SNR	 21.6	(2.8)	 21.7	(2.80)	 -.076	 .939	
Line	width	 6.2	(1.8)	 6.4	(1.28)	 -.284	 .778	
GABA/Creatine	 .4	(.1)	 .3	(.05)	 1.546	 .130	
GABA	%	CRLB	 5.5	(1.0)	 5.9	(1.4)	 -1.052	 .300	
Glutamate/Creatine	 .5	(.1)	 5.5	(.1)	 -.769	 .446	 	
Glutamate	%	CRLB	 7.6	(1.5)	 6.6	(1.5)	 2.001	 .053	 	
Glx/Creatine	 .8	(.1)	 .8	(.1)	 -.255	 .800	 	
Glx	%	CRLB	 5.6	(1.4)	 5.2	(1.5)	 .835	 .409	 	
N-Acetyl-
Aspartate/Creatine	
1.1	(.1)	 1.1	(1.1)	 .823	 .415	 	
N-Acetyl-Aspartate	%	
CRLB	
1.15	(.37)	 1.63	(1.34)	 -1.512	 .146	 	
	
CAARMS,	Clinical	Assessment	for	At-Risk	Mental	States;	CRLB:	Cramer	Rao	Lower	Bounds;	
GABA,	gamma-aminobutyric	acid;	Glx,	glutamate	+	glutamine	ratio;	HC,	healthy	control	
subjects;	SNR:	signal	to	noise	ratio;	UHR,	ultra-high	risk	subjects.	
	
	
	
